Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
暂无分享,去创建一个
Amar Gajjar | Mehmet Kocak | Arzu Onar-Thomas | Thomas E Merchant | T. Merchant | R. Gilbertson | A. Davidoff | J. Baker | S. Kaste | A. Gajjar | C. Stewart | A. Onar-Thomas | Richard J Gilbertson | Michael Tagen | Clinton F Stewart | Atmaram S. Pai Panandiker | A. Broniscer | M. Tagen | Alberto Broniscer | Atmaram S Pai Panandiker | Andrew M Davidoff | Thomas K Chin | Justin N Baker | Sue C Kaste | Wing Leung | Christopher Rowland | T. Chin | C. Rowland | M. Koçak | W. Leung
[1] H. Vogel,et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. , 2010, The Journal of clinical investigation.
[2] D. Hargrave,et al. Diffuse brainstem glioma in children: critical review of clinical trials. , 2006, The Lancet. Oncology.
[3] D. Hallahan,et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. , 2001, Cancer research.
[4] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[5] S. Kunze,et al. Autocrine Pathways of the Vascular Endothelial Growth Factor (VEGF) in Glioblastoma Multiforme: Clinical Relevance of Radiation-Induced Increase of VEGF Levels , 2004, Journal of Neuro-Oncology.
[6] T. Salcedo,et al. Incisor Degeneration in Rats Induced by Vascular Endothelial Growth Factor/Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibition , 2010, Toxicologic pathology.
[7] I. Pollack,et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. , 2007, Neuro-oncology.
[8] R. Herbst,et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Baker,et al. Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma , 2010, Cancer.
[10] H. Hurwitz,et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] N. Saijo,et al. A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] G. Lucchini,et al. Encephalopathy syndrome in children with hemato‐oncological disorders is not always posterior and reversible , 2008, Pediatric blood & cancer.
[13] R. Weichselbaum,et al. Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .
[14] R. Khan,et al. Posterior reversible encephalopathy syndrome in children with cancer , 2007, Pediatric blood & cancer.
[15] C. Ozcan,et al. Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.
[16] P. Wen,et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. , 2010, International journal of radiation oncology, biology, physics.
[17] Adam Dicker,et al. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. , 2004, International journal of radiation oncology, biology, physics.
[18] F. Westwood,et al. Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate , 2006, Toxicologic pathology.
[19] B. Lane,et al. Reversible posterior leukoencephalopathy syndrome and bevacizumab. , 2006, The New England journal of medicine.
[20] R. McLendon,et al. ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors , 2005, Clinical Cancer Research.
[21] M. Bernstein,et al. Prospective study of awake craniotomy used routinely and nonselectively for supratentorial tumors. , 2007, Journal of neurosurgery.
[22] Catherine Wheeler,et al. A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer , 2005, Clinical Cancer Research.
[23] L R Caplan,et al. A reversible posterior leukoencephalopathy syndrome. , 1996, The New England journal of medicine.
[24] Georg Breier,et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.
[25] Chih-hsun Yang,et al. Severe photosensitivity reaction to vandetanib. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Brada. Pathology and Genetics of Tumours of the Nervous System , 2001, British Journal of Cancer.
[27] J. Olson,et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] N. Boddaert,et al. Stereotactic biopsy of diffuse pontine lesions in children. , 2007, Journal of neurosurgery.
[29] C. Hawkins,et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Prados,et al. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. , 2008, Neuro-oncology.
[31] J. K. Smith,et al. Dexamethasone-induced posterior reversible encephalopathy syndrome. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] R. Weichselbaum,et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. , 1999, Cancer research.
[33] G. Fontanini,et al. Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma , 2005, Clinical Cancer Research.